MeiraGTx Unveils Breakthrough Gene Therapies for Obesity and Neurodegenerative Diseases at ASGCT 2025
MeiraGTx presented four posters at ASGCT 2025, showcasing advancements in gene therapies for severe pediatric obesity, ALS, and frontotemporal dementia, highlighting their innovative approach to addressing significant unmet medical needs.
MeiraGTx and Hologen AI Form $430 Million Strategic Collaboration to Advance Parkinson's Disease Gene Therapy
MeiraGTx has secured a strategic collaboration with Hologen AI that includes a $200 million upfront payment and the formation of a joint venture with an additional $230 million in committed capital to advance AAV-GAD gene therapy for Parkinson's disease.
Mass General Brigham Reports Universal Patient Response in Corneal Stem Cell Therapy Trial
Mass General Brigham's corneal stem cell therapy trial demonstrates positive outcomes across all enrolled patients, marking a significant advancement in regenerative eye treatment.
Breakthrough Gene Therapy Restores Vision in Children with Rare Genetic Blindness
A groundbreaking gene therapy developed by Moorfields Eye Hospital and MeiraGTx has successfully restored vision in children born with LCA-AIPL1, a severe inherited eye disorder affecting 2-3 in 10 million newborns.
MeiraGTx's AAV2-hAQP1 Receives FDA RMAT Designation for Radiation-Induced Xerostomia
MeiraGTx's AAV2-hAQP1 gene therapy has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for grade 2/3 radiation-induced xerostomia (RIX).
Gene Therapy and GPR6 Inverse Agonist Show Promise in Parkinson's Disease Trials
AAV-GAD gene therapy demonstrated safety and improved motor scores by boosting GABA levels in the subthalamic nucleus in a Parkinson's disease trial.
MeiraGTx's AAV-GAD Gene Therapy Shows Promise in Parkinson's Disease Phase I/II Trial
MeiraGTx's AAV-GAD gene therapy met its primary endpoint, demonstrating safety and tolerability in a Phase I/II trial for Parkinson's disease.
Pfizer Invests in Molecular Glue Research; Jazz's Zepzelca Shows Promise in Lung Cancer
Pfizer has invested $49 million in Triana Biomedicines to discover novel molecular glue degraders for oncology, with Pfizer holding an exclusive option to license promising candidates.